290O - Effect of sentinel node mapping strategy in robotic surgical treatment of endometrial cancers (290O)

Date 18 November 2017
Event ESMO Asia 2017 Congress
Session Gynaecological cancers
Topics Endometrial Cancer
Gynaecologic Malignancies
Surgical oncology
Radiation oncology
Presenter Tien Le
Citation Annals of Oncology (2017) 28 (suppl_10): x86-x93. 10.1093/annonc/mdx663
Authors T. Le1, R. Samany1, Z. Eslami2
  • 1Gynecology, The Ottawa Hospital Regional Cancer Centre, K1H 8L6 - Ottawa/CA
  • 2Pathology, The Ottawa Hospital Regional Cancer Centre, K1H 8L6 - Ottawa/CA



Surgical staging is recommended to prognosticate and plan adjuvant therapy. Sentinel lymph node (SLN) mapping has been studied as an alternative to full lymphadenectomy in surgical staging protocol. We report our experience with SLN mapping using blue dye under robotic platform.


All patients with clinically stage 1 endometrial carcinoma undergoing robotic assisted staging surgery were retrospectively reviewed. Total hysterectomy/BSO and pelvic lymphadenectomy is frequently used. One surgeon routinely apply SLN mapping in all cases using methylene blue dye. Standard patients’ demographics, pathology, and treatment related variables were abstracted. Descriptive, Chi Square and logistic regression were used to summarize, and detect significant associations between clinical variables and the detection of nodal metastasis. Cox regression was used to model time to disease recurrence.


From Nov 2011 to May 2016, 469 patients underwent robotic assisted staging. Full lymphadenectomy was done in 409 patients with 60 patients had SLN mapping. 372 patients (79%) had grade 1 on preop biopsy with 290 (78%) confirmed grade 1 based on final hysterectomy. There was significant association between tumour size (>2cm) and upgraded final tumour grade (OR 1.24 p = 0.005). There was no association between SLN mapping use and tumour grade, depth of invasion, LVSI, cervical stromal invasion. Nodal metastasis was observed in 5/409 (1.2%) lymphadenectomy patients versus 5/60 (8.3%) patients with SLN mapping (p 


SLN mapping can improve the sensitivity of detection of modal metastasis with no increased risk for recurrence in low risk disease.

Clinical trial identification

Legal entity responsible for the study

Dr Tien Le




All authors have declared no conflicts of interest.